Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
AbCellera Biologics Inc.

AbCellera Biologics Inc. (ABCL) Stock Overview

Explore AbCellera Biologics Inc.’s financial performance, market position, analyst ratings, and future outlook.

ABCL●NASDAQ
HealthcareBiotechnology
$14.82
$0.90(6.47%)
U.S. Market opens in 9h 53m

AbCellera Biologics Inc. (ABCL)

Meyka AI Score

Z

Key Financials

Market Cap4.5B
P/E Ratio-27.58
EPS (TTM)$-0.54
ROE-0.17%
Fundamental Analysis

AI Price Forecasts

1 Month$13.52
3 Months$10.82
1 Year Target$7.83

ABCL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of AbCellera Biologics Inc. (NASDAQ: ABCL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, AbCellera Biologics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ABCL on the NASDAQ shows an RSI of 76.95, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $7.83 for the NASDAQ listing.

Key metrics behind AbCellera Biologics Inc.'s NASDAQ-traded stock include a P/E ratio of -27.58 and a market capitalization of 4.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ABCL on the NASDAQ.

Price Performance (NASDAQ: ABCL)

1-Day Change
6.47%
5-Day Change
23.29%
1-Month Change
30.57%
3-Month Change
82.51%
6-Month Change
353.21%
Year-to-Date (YTD) Change
333.33%
1-Year Change
204.31%
3-Year Change
222.17%
5-Year Change
-23.80%
All-Time (Max) Change
-74.84%

Contact Information

https://www.abcellera.com
604 559 9005
150 W 4th Ave, Vancouver, BC, V5Y 1G6

Company Facts

5,620 Employees
IPO DateDec 11, 2020
CountryCA
Actively Trading

Frequently Asked Questions